SG11201907451XA - Substituted imidazo-quinolines as nlrp3 modulators - Google Patents
Substituted imidazo-quinolines as nlrp3 modulatorsInfo
- Publication number
- SG11201907451XA SG11201907451XA SG11201907451XA SG11201907451XA SG11201907451XA SG 11201907451X A SG11201907451X A SG 11201907451XA SG 11201907451X A SG11201907451X A SG 11201907451XA SG 11201907451X A SG11201907451X A SG 11201907451XA SG 11201907451X A SG11201907451X A SG 11201907451XA
- Authority
- SG
- Singapore
- Prior art keywords
- princeton
- route
- line road
- international
- province line
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Optical Communication System (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Transducers For Ultrasonic Waves (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762460677P | 2017-02-17 | 2017-02-17 | |
US201762490881P | 2017-04-27 | 2017-04-27 | |
US201762573991P | 2017-10-18 | 2017-10-18 | |
PCT/US2018/018484 WO2018152396A1 (en) | 2017-02-17 | 2018-02-16 | Substituted imidazo-quinolines as nlrp3 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907451XA true SG11201907451XA (en) | 2019-09-27 |
Family
ID=61283434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907451XA SG11201907451XA (en) | 2017-02-17 | 2018-02-16 | Substituted imidazo-quinolines as nlrp3 modulators |
Country Status (29)
Country | Link |
---|---|
US (4) | US10533005B2 (ja) |
EP (2) | EP3510034B1 (ja) |
JP (1) | JP7003143B6 (ja) |
KR (1) | KR102329062B1 (ja) |
CN (1) | CN110325534B (ja) |
AU (1) | AU2018221076B2 (ja) |
BR (1) | BR112019016625A2 (ja) |
CA (1) | CA3053949A1 (ja) |
CL (1) | CL2019002324A1 (ja) |
CO (1) | CO2019008932A2 (ja) |
CY (1) | CY1123305T1 (ja) |
DK (1) | DK3510034T3 (ja) |
ES (1) | ES2799900T3 (ja) |
HR (1) | HRP20201087T1 (ja) |
HU (1) | HUE050965T2 (ja) |
IL (1) | IL268640B (ja) |
LT (1) | LT3510034T (ja) |
ME (1) | ME03801B (ja) |
MX (1) | MX2019009788A (ja) |
MY (1) | MY194054A (ja) |
PE (1) | PE20191552A1 (ja) |
PL (1) | PL3510034T3 (ja) |
PT (1) | PT3510034T (ja) |
RS (1) | RS60548B1 (ja) |
SG (1) | SG11201907451XA (ja) |
SI (1) | SI3510034T1 (ja) |
TW (1) | TWI674261B (ja) |
WO (1) | WO2018152396A1 (ja) |
ZA (1) | ZA201906104B (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
US11344543B2 (en) | 2017-07-14 | 2022-05-31 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
SG11201912166XA (en) | 2017-07-24 | 2020-02-27 | Novartis Inflammasome Research Inc | Compounds and compositions for treating conditions associated with nlrp activity |
MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
MA50398B1 (fr) | 2017-10-18 | 2021-10-29 | Incyte Corp | Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma |
EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
CN112888677A (zh) | 2018-08-16 | 2021-06-01 | 先天肿瘤免疫公司 | 被取代的4-氨基-1H-咪唑并[4,5-c]喹啉化合物及其改进的制备方法 |
CN113038989A (zh) * | 2018-08-16 | 2021-06-25 | 先天肿瘤免疫公司 | 咪唑并[4,5-c]喹啉衍生的nlrp3调节剂 |
CN112996567A (zh) | 2018-08-16 | 2021-06-18 | 先天肿瘤免疫公司 | 咪唑并[4,5-c]喹啉衍生的nlrp3-调节剂 |
CN117088871A (zh) * | 2018-11-30 | 2023-11-21 | 四川科伦博泰生物医药股份有限公司 | 并环化合物、其制备方法及用途 |
EP3911642A1 (en) * | 2019-01-14 | 2021-11-24 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
WO2020150115A1 (en) * | 2019-01-14 | 2020-07-23 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
US20220056043A1 (en) | 2019-02-19 | 2022-02-24 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nitrogen-containing fused cyclic compound, preparation method therefor and use thereof |
JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Her2を標的とする免疫結合体 |
CN114901275A (zh) * | 2019-12-20 | 2022-08-12 | 纳米医疗有限公司 | 可用于治疗癌症的含有Toll样受体(“TLR”)激动剂前药的配制和/或共同配制的脂质体组合物及其方法 |
KR102409345B1 (ko) * | 2020-09-22 | 2022-06-16 | 가톨릭대학교 산학협력단 | Nlrp3 인플라마좀 억제제 및 이의 용도 |
CN116874340B (zh) * | 2023-07-10 | 2024-04-05 | 湖北航天化学技术研究所 | 一种苯基炸药类含能共晶化合物及其制备方法 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US948029A (en) * | 1909-04-23 | 1910-02-01 | James Harvey Leffler | Reclining-chair. |
CA1271477A (en) | 1983-11-18 | 1990-07-10 | John F. Gerster | 1h-imidazo[4,5-c]quinolin-4-amines |
CZ285050B6 (cs) * | 1991-03-01 | 1999-05-12 | Minnesota Mining And Manufacturing Company | 1-Substituované, 2-substituované-1H-imidazo/4,5-c /chinolin-4-aminy |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
JPH1180156A (ja) | 1997-09-04 | 1999-03-26 | Hokuriku Seiyaku Co Ltd | 1−(置換アリール)アルキル−1h−イミダゾピリジン−4−アミン誘導体 |
MXPA01006422A (es) | 1998-12-23 | 2002-06-04 | Pfizer Inc Abgenix Inc | Anticuerpos monoclonales humanos de ctla-4. |
MXPA02001911A (es) | 1999-08-24 | 2003-07-21 | Medarex Inc | Anticuerpos ctla-4 humanos y sus usos. |
GB0023008D0 (en) | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
MXPA05006740A (es) | 2002-12-20 | 2005-10-05 | 3M Innovative Properties Co | Imidazoquinolinas arilo-sustituidas. |
JP2006517974A (ja) | 2003-02-13 | 2006-08-03 | スリーエム イノベイティブ プロパティズ カンパニー | Irm化合物およびトル様受容体8に関する方法および組成物 |
AU2004266657B2 (en) | 2003-08-14 | 2009-07-02 | 3M Innovative Properties Company | Lipid-modified immune response modifiers |
AU2004268625B2 (en) | 2003-08-27 | 2011-03-31 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
ATE465742T1 (de) | 2003-09-05 | 2010-05-15 | Anadys Pharmaceuticals Inc | Tlr7-liganden zur behandlung von hepatitis c |
KR101130928B1 (ko) | 2003-11-25 | 2012-04-12 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 치환된 이미다조 고리 시스템 및 방법 |
JP2007513170A (ja) | 2003-12-04 | 2007-05-24 | スリーエム イノベイティブ プロパティズ カンパニー | スルホン置換イミダゾ環エーテル |
US8697873B2 (en) | 2004-03-24 | 2014-04-15 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
JP2007530579A (ja) | 2004-06-10 | 2007-11-01 | スリーエム イノベイティブ プロパティズ カンパニー | アミド置換イミダゾピリジン、イミダゾキノリン、およびイミダゾナフチリジン |
US20080015184A1 (en) * | 2004-06-14 | 2008-01-17 | 3M Innovative Properties Company | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines |
WO2005123080A2 (en) | 2004-06-15 | 2005-12-29 | 3M Innovative Properties Company | Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
US20070259881A1 (en) | 2004-06-18 | 2007-11-08 | Dellaria Joseph F Jr | Substituted Imidazo Ring Systems and Methods |
US7915281B2 (en) | 2004-06-18 | 2011-03-29 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method |
CN101056877B (zh) | 2004-09-14 | 2010-06-09 | 诺华疫苗和诊断公司 | 咪唑并喹啉化合物 |
WO2006073940A2 (en) | 2004-12-30 | 2006-07-13 | 3M Innovative Properties Company | Multi-route administration of immune response modifier compounds |
AU2006216997A1 (en) * | 2005-02-11 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Substituted imidazoquinolines and imidazonaphthyridines |
US8178677B2 (en) | 2005-02-23 | 2012-05-15 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazoquinolines |
US8158794B2 (en) | 2005-02-23 | 2012-04-17 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
CA3201163A1 (en) | 2005-07-01 | 2007-01-11 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
WO2007079086A1 (en) | 2005-12-28 | 2007-07-12 | Coley Pharmaceutical Group, Inc. | Pyrazoloalkyl substituted imidazo ring compounds and methods |
US8436178B2 (en) | 2007-05-08 | 2013-05-07 | Astrazeneca Ab | Imidazoquinolines with immuno-modulating properties |
ES2616355T3 (es) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Anticuerpos para el receptor humano de muerte programada PD-1 |
EP2009002A1 (en) | 2007-06-21 | 2008-12-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems |
HRP20240240T1 (hr) | 2008-12-09 | 2024-04-26 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
RU2625034C2 (ru) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Антитела и другие молекулы, которые связывают в7-н1 и pd-1 |
US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
US9034336B2 (en) * | 2011-08-30 | 2015-05-19 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
DK2785375T3 (da) | 2011-11-28 | 2020-10-12 | Merck Patent Gmbh | Anti-pd-l1-antistoffer og anvendelser deraf |
SG10201700698WA (en) | 2012-05-15 | 2017-02-27 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
CN104736168B (zh) | 2012-05-31 | 2018-09-21 | 索伦托治疗有限公司 | 与pd-l1结合的抗原结合蛋白 |
EP2674170B1 (en) * | 2012-06-15 | 2014-11-19 | Invivogen | Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids |
US9295732B2 (en) | 2013-02-22 | 2016-03-29 | Invivogen | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists |
RU2723050C2 (ru) | 2013-05-02 | 2020-06-08 | Анаптисбайо, Инк. | Антитела, направленные к белку запрограммированной гибели клетки-1 (pd-1) |
SG11201508273RA (en) | 2013-05-18 | 2015-12-30 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
CN105683217B (zh) | 2013-05-31 | 2019-12-10 | 索伦托治疗有限公司 | 与pd-1结合的抗原结合蛋白 |
US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
HRP20221262T1 (hr) | 2013-09-13 | 2022-12-09 | Beigene Switzerland Gmbh | Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava |
PL3081576T3 (pl) | 2013-12-12 | 2020-03-31 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne |
WO2015095780A1 (en) | 2013-12-20 | 2015-06-25 | The University Of Kansas | Toll-like receptor 8 agonists |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
CN112546230A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
GB201418004D0 (en) | 2014-10-10 | 2014-11-26 | Isis Innovation | Polymer adjuvant |
MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
CA2986765A1 (en) | 2015-05-29 | 2016-12-08 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
KR20220131277A (ko) | 2015-09-01 | 2022-09-27 | 아게누스 인코포레이티드 | 항-pd-1 항체 및 이를 이용하는 방법 |
US20170056448A1 (en) | 2015-09-01 | 2017-03-02 | Ifm Therapeutics, Inc | Immune cells having increased immunity or resistance to an immunosuppressive cytokine and use of the same |
CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-egfr组合 |
US10730871B2 (en) | 2016-01-28 | 2020-08-04 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
CN111491361B (zh) | 2016-02-02 | 2023-10-24 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
KR20180134395A (ko) | 2016-04-19 | 2018-12-18 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
US10533007B2 (en) | 2016-04-19 | 2020-01-14 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
-
2018
- 2018-02-14 TW TW107105417A patent/TWI674261B/zh active
- 2018-02-16 EP EP18707612.0A patent/EP3510034B1/en active Active
- 2018-02-16 MX MX2019009788A patent/MX2019009788A/es unknown
- 2018-02-16 SI SI201830085T patent/SI3510034T1/sl unknown
- 2018-02-16 WO PCT/US2018/018484 patent/WO2018152396A1/en unknown
- 2018-02-16 AU AU2018221076A patent/AU2018221076B2/en active Active
- 2018-02-16 MY MYPI2019004704A patent/MY194054A/en unknown
- 2018-02-16 JP JP2019544636A patent/JP7003143B6/ja active Active
- 2018-02-16 SG SG11201907451XA patent/SG11201907451XA/en unknown
- 2018-02-16 CN CN201880012493.7A patent/CN110325534B/zh active Active
- 2018-02-16 RS RS20200830A patent/RS60548B1/sr unknown
- 2018-02-16 PL PL18707612T patent/PL3510034T3/pl unknown
- 2018-02-16 US US15/898,258 patent/US10533005B2/en active Active
- 2018-02-16 LT LTEP18707612.0T patent/LT3510034T/lt unknown
- 2018-02-16 PE PE2019001718A patent/PE20191552A1/es unknown
- 2018-02-16 DK DK18707612.0T patent/DK3510034T3/da active
- 2018-02-16 HU HUE18707612A patent/HUE050965T2/hu unknown
- 2018-02-16 KR KR1020197026922A patent/KR102329062B1/ko active IP Right Grant
- 2018-02-16 EP EP20169634.1A patent/EP3753938B1/en active Active
- 2018-02-16 BR BR112019016625A patent/BR112019016625A2/pt active Search and Examination
- 2018-02-16 CA CA3053949A patent/CA3053949A1/en active Pending
- 2018-02-16 ME MEP-2020-149A patent/ME03801B/me unknown
- 2018-02-16 ES ES18707612T patent/ES2799900T3/es active Active
- 2018-02-16 PT PT187076120T patent/PT3510034T/pt unknown
-
2019
- 2019-08-12 IL IL268640A patent/IL268640B/en unknown
- 2019-08-16 CL CL2019002324A patent/CL2019002324A1/es unknown
- 2019-08-16 CO CONC2019/0008932A patent/CO2019008932A2/es unknown
- 2019-09-16 ZA ZA2019/06104A patent/ZA201906104B/en unknown
- 2019-11-25 US US16/693,420 patent/US20200157096A1/en not_active Abandoned
-
2020
- 2020-07-13 HR HRP20201087TT patent/HRP20201087T1/hr unknown
- 2020-07-16 CY CY20201100649T patent/CY1123305T1/el unknown
-
2021
- 2021-05-06 US US17/313,319 patent/US11827632B2/en active Active
-
2023
- 2023-10-17 US US18/488,092 patent/US20240067649A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
SG11201809082WA (en) | Nlrp3 modulators | |
SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
SG11201908813QA (en) | Anti-sirp alpha antibodies | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201906465YA (en) | Tigit- and light-based chimeric proteins | |
SG11201900619XA (en) | Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors | |
SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201810177VA (en) | Pet-imaging immunomodulators | |
SG11201901937WA (en) | Pyridine compound | |
SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201906958TA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
SG11201906947SA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |